The mechanism: Biogen's entire Alzheimer's franchise rests on a single piece of paper: National Coverage Determination 200.3, the CMS rule that lets Medicare pay for anti-amyloid antibodies like Leqembi. That NCD isn't statute — it's an administrative determination CMS itself wrote in 2022 and loosened in 2023, and what CMS writes, CMS can revisit. With HHS under new leadership newly hostile to expensive interventions with thin outcome data and openly gutting other big-ticket coverage pathways (it's already moved to unwind favorable reimbursement treatment for breakthrough-designated devices), a re-opened NCD proceeding on amyloid antibodies — tightening the mild-cognitive-impairment eligibility window, reinstating tougher registry/CED evidence bars, or trimming diagnostic-imaging coverage — is a live tail risk that Wall Street is pricing as background noise. It isn't. Medicare is essentially the entire addressable market for a drug given to elderly MCI/mild-AD patients; a narrower NCD doesn't dent Leqembi's growth curve, it deletes it.
Who cashes in: If CMS moves to re-tighten amyloid-drug coverage, capital simply rotates to Alzheimer's approaches that don't depend on the same fragile coverage clause. Amgen (AMGN) is running late-stage anti-tau and combination Alzheimer's programs that would inherit share of voice (and eventually share of spend) if amyloid-only NCD risk becomes a market theme — its diversified base means an AD setback for Biogen isn't existential for anyone rotating capital its way. Vertex (VRTX) and Intellia (NTLA) aren't Alzheimer's plays today, but both are the natural landing spots for generalist biotech money exiting a name whose thesis has become "one CMS memo away from re-rating" — capital doesn't sit in cash, it rotates to names with mechanism diversity and gene-editing/curative optionality that isn't hostage to a single reimbursement determination.